Literature DB >> 4723265

Pharmacokinetics of methotrexate.

D H Huffman, S H Wan, D L Azarnoff, B Hogstraten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4723265     DOI： 10.1002/cpt1973144part1572

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  48 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  A pharmacokinetic model for high-dose methotrexate infusions in man.

Authors:  S D Reich; N R Bachur; R H Goebel; M Berman
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

Authors:  H Iven; H Brasch; J Engster
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.

Authors:  A L Stewart; J M Margison; P M Wilkinson; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

Authors:  S D Reich
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Authors:  P J Kearney; P A Light; A Preece; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

Authors:  F Lokiec; O Poirier; C Gisselbrecht; M Marty; M Boiron; Y Najean
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.

Authors:  B M Colls; R A Robson; B A Robinson; G W Tisch
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.